

From: 5.1.2.e Woo)
Sent: dinsdag 21 april 2020 14:17
To: 5.1.2.e Woo @ec.europa.eu'
Cc: 5.1.2.e Woo , dr. 5.1.2.e Woo); 5.1.2.e Woo
Subject: NL comments C.03 mancozeb

Dear 5.1.2.e Woo

Hope you are well! Please find below our comments on the draft COM-proposal for the non-renewal of mancozeb. Please note that NL does not yet have a final position.

The Ctgb agrees with the Commission's draft proposal that based on the currently available outcome of the peer review a non-renewal of mancozeb is appropriate, considering the classification as Reprotox 1B, the endocrine disrupting properties and the identified risks to humans and the environment. Considering this outcome, the Ctgb urges the Commission to ensure that the decision on the Commission's proposal is made as soon as possible.

The Ctgb also took note of the statement of RMS 5.1.2.a Woo. In our opinion, the statement does not confirm the allegations of the applicants that RMS 5.1.2.a omitted to assess available data that is essential for the conclusion of the risk assessment. The Ctgb asks the Commission to share the Commission's views with regard to these allegations and the statement of the RMS, so that this discussion can be closed and further delays of the decision-making process can be prevented.

Many thanks for taking our comments into consideration.

Best regards,

5.1.2.e Woo

Ctgb